G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and relaxing, because that predictable routine of meetings, deadline, and whatnot has, of course, returned. And this may take a bit more adjustment than usual on this side of the pond, given that so many took an extended holiday last week. Our suggestion for handling this re-entry is to quaff a cup or three of stimulation. Firing up the neurons is a good thing. Meanwhile, here are some tidbits to help you ease back in. Have a smashing day and do keep in touch …

There may be a glimmer of hope in the fight to protect people from HIV-1, the most widespread type of the virus and the one that causes the most disease globally, CNN says. A new vaccine appears to be safe and induced an immune response in humans and rhesus monkeys in an early stage trial, according to new research in The Lancet. That means it’s safe enough to go into the next phase of testing, which involves a larger number of humans. It’s one of only five experimental HIV-1 vaccine concepts that have gotten this far during the 35 years of the HIV pandemic.

A newly unsealed lawsuit by Tennessee’s attorney general says Purdue Pharma directed its sales force to target the highest prescribers, many with limited or no pain management background or training, the Associated Press writes. The 274-page lawsuit says Purdue violated a 2007 settlement with the state, placing profits over people with a deceptive narrative that claimed its opioids were safer than they actually were, and that the company targeted vulnerable people, including the elderly, while relying on continued users and high doses.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy